These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 38596266)

  • 21. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease.
    Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group
    Kidney Int; 2021 Mar; 99(3S):S1-S87. PubMed ID: 33637192
    [No Abstract]   [Full Text] [Related]  

  • 22. Metabolic and Anti-inflammatory Response to Melatonin Administration in Patients with Diabetic Nephropathy.
    Satari M; Bahmani F; Reiner Z; Soleimani A; Aghadavod E; Kheiripour N; Asemi Z
    Iran J Kidney Dis; 2021 Jan; 1(1):22-30. PubMed ID: 33492301
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Disorders in bone-mineral parameters and the risk of death in persons with chronic kidney disease stages 4 and 5: the PECERA study.
    Molina P; Molina MD; Pallardó LM; Torralba J; Escudero V; Álvarez L; Peris A; Sánchez-Pérez P; González-Rico M; Puchades MJ; Fernández-Nájera JE; Giménez-Civera E; D'Marco L; Carrero JJ; Górriz JL
    J Nephrol; 2021 Aug; 34(4):1189-1199. PubMed ID: 33394344
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aldosterone synthase inhibitors for cardiovascular diseases: A comprehensive review of preclinical, clinical and in silico data.
    Lenzini L; Zanotti G; Bonchio M; Rossi GP
    Pharmacol Res; 2021 Jan; 163():105332. PubMed ID: 33271294
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.
    Bakris GL; Agarwal R; Anker SD; Pitt B; Ruilope LM; Rossing P; Kolkhof P; Nowack C; Schloemer P; Joseph A; Filippatos G;
    N Engl J Med; 2020 Dec; 383(23):2219-2229. PubMed ID: 33264825
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dapagliflozin in Patients with Chronic Kidney Disease.
    Heerspink HJL; Stefánsson BV; Correa-Rotter R; Chertow GM; Greene T; Hou FF; Mann JFE; McMurray JJV; Lindberg M; Rossing P; Sjöström CD; Toto RD; Langkilde AM; Wheeler DC;
    N Engl J Med; 2020 Oct; 383(15):1436-1446. PubMed ID: 32970396
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Triglycerides to High-Density Lipoprotein Cholesterol Ratio Predicts Chronic Renal Disease in Patients without Diabetes Mellitus (STELLA Study).
    Raikou VD; Kyriaki D; Gavriil S
    J Cardiovasc Dev Dis; 2020 Aug; 7(3):. PubMed ID: 32752179
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of an Omega-3 Fatty Acid Supplement in Patients With Predialysis Chronic Kidney Disease.
    Bunout D; Barrera G; Hirsch S; Lorca E
    J Ren Nutr; 2021 Jan; 31(1):64-72. PubMed ID: 32732154
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dietary intake of total, animal, and plant proteins and risk of all cause, cardiovascular, and cancer mortality: systematic review and dose-response meta-analysis of prospective cohort studies.
    Naghshi S; Sadeghi O; Willett WC; Esmaillzadeh A
    BMJ; 2020 Jul; 370():m2412. PubMed ID: 32699048
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Esaxerenone, a novel nonsteroidal mineralocorticoid receptor blocker (MRB) in hypertension and chronic kidney disease.
    Wan N; Rahman A; Nishiyama A
    J Hum Hypertens; 2021 Feb; 35(2):148-156. PubMed ID: 32661269
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aldosterone and the mineralocorticoid receptor in renal injury: A potential therapeutic target in feline chronic kidney disease.
    Spencer S; Wheeler-Jones C; Elliott J
    J Vet Pharmacol Ther; 2020 May; 43(3):243-267. PubMed ID: 32128854
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chronic kidney disease: Biomarker diagnosis to therapeutic targets.
    Wang YN; Ma SX; Chen YY; Chen L; Liu BL; Liu QQ; Zhao YY
    Clin Chim Acta; 2019 Dec; 499():54-63. PubMed ID: 31476302
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency.
    Levey AS; Gansevoort RT; Coresh J; Inker LA; Heerspink HL; Grams ME; Greene T; Tighiouart H; Matsushita K; Ballew SH; Sang Y; Vonesh E; Ying J; Manley T; de Zeeuw D; Eckardt KU; Levin A; Perkovic V; Zhang L; Willis K
    Am J Kidney Dis; 2020 Jan; 75(1):84-104. PubMed ID: 31473020
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial.
    Mosenzon O; Wiviott SD; Cahn A; Rozenberg A; Yanuv I; Goodrich EL; Murphy SA; Heerspink HJL; Zelniker TA; Dwyer JP; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Kato ET; Gause-Nilsson IAM; Fredriksson M; Johansson PA; Langkilde AM; Sabatine MS; Raz I
    Lancet Diabetes Endocrinol; 2019 Aug; 7(8):606-617. PubMed ID: 31196815
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
    Perkovic V; Jardine MJ; Neal B; Bompoint S; Heerspink HJL; Charytan DM; Edwards R; Agarwal R; Bakris G; Bull S; Cannon CP; Capuano G; Chu PL; de Zeeuw D; Greene T; Levin A; Pollock C; Wheeler DC; Yavin Y; Zhang H; Zinman B; Meininger G; Brenner BM; Mahaffey KW;
    N Engl J Med; 2019 Jun; 380(24):2295-2306. PubMed ID: 30990260
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chronic Renal Changes After a Single Ischemic Event in an Experimental Model of Feline Chronic Kidney Disease.
    Brown CA; Rissi DR; Dickerson VM; Davis AM; Brown SA; Schmiedt CW
    Vet Pathol; 2019 Jul; 56(4):536-543. PubMed ID: 30895907
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
    Wiviott SD; Raz I; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Silverman MG; Zelniker TA; Kuder JF; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Ruff CT; Gause-Nilsson IAM; Fredriksson M; Johansson PA; Langkilde AM; Sabatine MS;
    N Engl J Med; 2019 Jan; 380(4):347-357. PubMed ID: 30415602
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Burden of cardio-renal-metabolic conditions in adults with type 2 diabetes within the Diabetes Collaborative Registry.
    Arnold SV; Kosiborod M; Wang J; Fenici P; Gannedahl G; LoCasale RJ
    Diabetes Obes Metab; 2018 Aug; 20(8):2000-2003. PubMed ID: 29577540
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association between Low Serum Bicarbonate Concentrations and Cardiovascular Disease in Patients in the End-Stage of Renal Disease.
    Raikou VD; Kyriaki D
    Diseases; 2016 Nov; 4(4):. PubMed ID: 28933414
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metabolic and hemodynamic effects of sodium-dependent glucose cotransporter 2 inhibitors on cardio-renal protection in the treatment of patients with type 2 diabetes mellitus.
    Kashiwagi A; Maegawa H
    J Diabetes Investig; 2017 Jul; 8(4):416-427. PubMed ID: 28178390
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.